Omics Based Clinical Trials - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB512244054

Publication Date:

December 3, 2024

Pages:

101

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Omics is听a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
The global market for Omics Based Clinical Trials was estimated to be worth US$ 2307 million in 2023 and is forecast to a readjusted size of US$ 2962 million by 2030 with a CAGR of 5.6% during the forecast period 2024-2030
Omics is听a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Omics Based Clinical Trials, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Omics Based Clinical Trials by region & country, by Type, and by Application.
The Omics Based Clinical Trials market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Omics Based Clinical Trials.
麻豆原创 Segmentation
By Company
Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer
Covance
Rebus Bio
Novo Nordisk
Segment by Type:
Interventional Studies
Observational Studies
Expanded Access Studies
Segment by Application
Oncology
Cardiology
Respiratory Diseases
Skin Diseases
CNS Diseases
Immunology
Genetic Diseases
Other Indications
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Omics Based Clinical Trials manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Omics Based Clinical Trials in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Omics Based Clinical Trials in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Omics Based Clinical Trials Product Introduction
1.2 Global Omics Based Clinical Trials 麻豆原创 Size Forecast
1.3 Omics Based Clinical Trials 麻豆原创 Trends & Drivers
1.3.1 Omics Based Clinical Trials Industry Trends
1.3.2 Omics Based Clinical Trials 麻豆原创 Drivers & Opportunity
1.3.3 Omics Based Clinical Trials 麻豆原创 Challenges
1.3.4 Omics Based Clinical Trials 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Omics Based Clinical Trials Players Revenue Ranking (2023)
2.2 Global Omics Based Clinical Trials Revenue by Company (2019-2024)
2.3 Key Companies Omics Based Clinical Trials Manufacturing Base Distribution and Headquarters
2.4 Key Companies Omics Based Clinical Trials Product Offered
2.5 Key Companies Time to Begin Mass Production of Omics Based Clinical Trials
2.6 Omics Based Clinical Trials 麻豆原创 Competitive Analysis
2.6.1 Omics Based Clinical Trials 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Omics Based Clinical Trials Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omics Based Clinical Trials as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Interventional Studies
3.1.2 Observational Studies
3.1.3 Expanded Access Studies
3.2 Global Omics Based Clinical Trials Sales Value by Type
3.2.1 Global Omics Based Clinical Trials Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Omics Based Clinical Trials Sales Value, by Type (2019-2030)
3.2.3 Global Omics Based Clinical Trials Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Oncology
4.1.2 Cardiology
4.1.3 Respiratory Diseases
4.1.4 Skin Diseases
4.1.5 CNS Diseases
4.1.6 Immunology
4.1.7 Genetic Diseases
4.1.8 Other Indications
4.2 Global Omics Based Clinical Trials Sales Value by Application
4.2.1 Global Omics Based Clinical Trials Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Omics Based Clinical Trials Sales Value, by Application (2019-2030)
4.2.3 Global Omics Based Clinical Trials Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Omics Based Clinical Trials Sales Value by Region
5.1.1 Global Omics Based Clinical Trials Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Omics Based Clinical Trials Sales Value by Region (2019-2024)
5.1.3 Global Omics Based Clinical Trials Sales Value by Region (2025-2030)
5.1.4 Global Omics Based Clinical Trials Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Omics Based Clinical Trials Sales Value, 2019-2030
5.2.2 North America Omics Based Clinical Trials Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Omics Based Clinical Trials Sales Value, 2019-2030
5.3.2 Europe Omics Based Clinical Trials Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Omics Based Clinical Trials Sales Value, 2019-2030
5.4.2 Asia Pacific Omics Based Clinical Trials Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Omics Based Clinical Trials Sales Value, 2019-2030
5.5.2 South America Omics Based Clinical Trials Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Omics Based Clinical Trials Sales Value, 2019-2030
5.6.2 Middle East & Africa Omics Based Clinical Trials Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Omics Based Clinical Trials Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Omics Based Clinical Trials Sales Value
6.3 United States
6.3.1 United States Omics Based Clinical Trials Sales Value, 2019-2030
6.3.2 United States Omics Based Clinical Trials Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Omics Based Clinical Trials Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Omics Based Clinical Trials Sales Value, 2019-2030
6.4.2 Europe Omics Based Clinical Trials Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Omics Based Clinical Trials Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Omics Based Clinical Trials Sales Value, 2019-2030
6.5.2 China Omics Based Clinical Trials Sales Value by Type (%), 2023 VS 2030
6.5.3 China Omics Based Clinical Trials Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Omics Based Clinical Trials Sales Value, 2019-2030
6.6.2 Japan Omics Based Clinical Trials Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Omics Based Clinical Trials Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Omics Based Clinical Trials Sales Value, 2019-2030
6.7.2 South Korea Omics Based Clinical Trials Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Omics Based Clinical Trials Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Omics Based Clinical Trials Sales Value, 2019-2030
6.8.2 Southeast Asia Omics Based Clinical Trials Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Omics Based Clinical Trials Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Omics Based Clinical Trials Sales Value, 2019-2030
6.9.2 India Omics Based Clinical Trials Sales Value by Type (%), 2023 VS 2030
6.9.3 India Omics Based Clinical Trials Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Parexel International Corporation
7.1.1 Parexel International Corporation Profile
7.1.2 Parexel International Corporation Main Business
7.1.3 Parexel International Corporation Omics Based Clinical Trials Products, Services and Solutions
7.1.4 Parexel International Corporation Omics Based Clinical Trials Revenue (US$ Million) & (2019-2024)
7.1.5 Parexel International Corporation Recent Developments
7.2 Pharmaceutical Product Development (PPD)
7.2.1 Pharmaceutical Product Development (PPD) Profile
7.2.2 Pharmaceutical Product Development (PPD) Main Business
7.2.3 Pharmaceutical Product Development (PPD) Omics Based Clinical Trials Products, Services and Solutions
7.2.4 Pharmaceutical Product Development (PPD) Omics Based Clinical Trials Revenue (US$ Million) & (2019-2024)
7.2.5 Pharmaceutical Product Development (PPD) Recent Developments
7.3 Charles River Laboratory
7.3.1 Charles River Laboratory Profile
7.3.2 Charles River Laboratory Main Business
7.3.3 Charles River Laboratory Omics Based Clinical Trials Products, Services and Solutions
7.3.4 Charles River Laboratory Omics Based Clinical Trials Revenue (US$ Million) & (2019-2024)
7.3.5 ICON plc Recent Developments
7.4 ICON plc
7.4.1 ICON plc Profile
7.4.2 ICON plc Main Business
7.4.3 ICON plc Omics Based Clinical Trials Products, Services and Solutions
7.4.4 ICON plc Omics Based Clinical Trials Revenue (US$ Million) & (2019-2024)
7.4.5 ICON plc Recent Developments
7.5 SGS SA
7.5.1 SGS SA Profile
7.5.2 SGS SA Main Business
7.5.3 SGS SA Omics Based Clinical Trials Products, Services and Solutions
7.5.4 SGS SA Omics Based Clinical Trials Revenue (US$ Million) & (2019-2024)
7.5.5 SGS SA Recent Developments
7.6 Eli Lilly and Company
7.6.1 Eli Lilly and Company Profile
7.6.2 Eli Lilly and Company Main Business
7.6.3 Eli Lilly and Company Omics Based Clinical Trials Products, Services and Solutions
7.6.4 Eli Lilly and Company Omics Based Clinical Trials Revenue (US$ Million) & (2019-2024)
7.6.5 Eli Lilly and Company Recent Developments
7.7 Pfizer
7.7.1 Pfizer Profile
7.7.2 Pfizer Main Business
7.7.3 Pfizer Omics Based Clinical Trials Products, Services and Solutions
7.7.4 Pfizer Omics Based Clinical Trials Revenue (US$ Million) & (2019-2024)
7.7.5 Pfizer Recent Developments
7.8 Covance
7.8.1 Covance Profile
7.8.2 Covance Main Business
7.8.3 Covance Omics Based Clinical Trials Products, Services and Solutions
7.8.4 Covance Omics Based Clinical Trials Revenue (US$ Million) & (2019-2024)
7.8.5 Covance Recent Developments
7.9 Rebus Bio
7.9.1 Rebus Bio Profile
7.9.2 Rebus Bio Main Business
7.9.3 Rebus Bio Omics Based Clinical Trials Products, Services and Solutions
7.9.4 Rebus Bio Omics Based Clinical Trials Revenue (US$ Million) & (2019-2024)
7.9.5 Rebus Bio Recent Developments
7.10 Novo Nordisk
7.10.1 Novo Nordisk Profile
7.10.2 Novo Nordisk Main Business
7.10.3 Novo Nordisk Omics Based Clinical Trials Products, Services and Solutions
7.10.4 Novo Nordisk Omics Based Clinical Trials Revenue (US$ Million) & (2019-2024)
7.10.5 Novo Nordisk Recent Developments
8 Industry Chain Analysis
8.1 Omics Based Clinical Trials Industrial Chain
8.2 Omics Based Clinical Trials Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Omics Based Clinical Trials Sales Model
8.5.2 Sales Channel
8.5.3 Omics Based Clinical Trials Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer
Covance
Rebus Bio
Novo Nordisk

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.